| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A therapeutic withdrawal can make a strategic advance
|
Jordon, V.C.
|
|
1992
|
3 |
8 |
p. 587-588
|
article
|
| 2 |
Awards, appointments
|
|
|
1992
|
3 |
8 |
p. 583-584
|
article
|
| 3 |
Book review
|
Bernier, J.
|
|
1992
|
3 |
8 |
p. 638-638
|
article
|
| 4 |
Book review
|
Hansen, H. H.
|
|
1992
|
3 |
8 |
p. 644-644
|
article
|
| 5 |
Book review
|
Sessa, C.
|
|
1992
|
3 |
8 |
p. 629-629
|
article
|
| 6 |
Classified advertisements from ESMO-members and meeting announcements
|
|
|
1992
|
3 |
8 |
p. 604-604
|
article
|
| 7 |
Contents of the next issue
|
|
|
1992
|
3 |
8 |
p. 579-579
|
article
|
| 8 |
Editorial: Antiosteolytic agents in the management of hypercalcemia
|
Bonjour, Jean-Philippe
|
|
1992
|
3 |
8 |
p. 595-595
|
article
|
| 9 |
Editorial: A therapeutic withdrawal can make a strategic advance
|
Jordan, V. C.
|
|
1992
|
3 |
8 |
p. 595-595
|
article
|
| 10 |
Editorial: Infusional anthracyclines: Is slower better? If so, why?
|
Workman, P.
|
|
1992
|
3 |
8 |
p. 595-595
|
article
|
| 11 |
ESO: A decade of cancer education and training in Europe
|
|
|
1992
|
3 |
8 |
p. 581-582
|
article
|
| 12 |
First ESMO course: A good beginning
|
|
|
1992
|
3 |
8 |
p. 584-584
|
article
|
| 13 |
Interferon alpha-2-beta enhances immunoscintigraphic localization of monoclonal antibody in malignant melanoma
|
Marroni, B. J.
|
|
1992
|
3 |
8 |
p. 664-664
|
article
|
| 14 |
In this issue
|
|
|
1992
|
3 |
8 |
p. 579-579
|
article
|
| 15 |
J.B. Lippincott Company
|
|
|
1992
|
3 |
8 |
p. 667-667
|
article
|
| 16 |
Mechanisms of hypercalcemia in lymphomas
|
Seymour, J.
|
|
1992
|
3 |
8 |
p. 664-665
|
article
|
| 17 |
MRS as an early indicator of tumour response
|
|
|
1992
|
3 |
8 |
p. 580-581
|
article
|
| 18 |
News: AIDS and cancer: Let's begin thinking globally
|
|
|
1992
|
3 |
8 |
p. 580-580
|
article
|
| 19 |
Original article: Chemotherapy with MACOP-B and VACOP-B for intermediate- and high-grade non-Hodgkin's lymphoma: Clinical results and analysis of prognostic factors
|
Pichert, G.
|
|
1992
|
3 |
8 |
p. 645-649
|
article
|
| 20 |
Original article: Long-term outcome and sequelae in aggressive lymphoma patients treated with the LNH-80 regimen
|
Dumontet, C.
|
|
1992
|
3 |
8 |
p. 639-644
|
article
|
| 21 |
Original article: Pharmacokinetics and metabolism of epirubicin administered as i.v. bolus and 48-h infusion in patients with advanced soft-tissue sarcoma
|
Robert, J.
|
|
1992
|
3 |
8 |
p. 651-656
|
article
|
| 22 |
Original article: Plicamycin and pamidronate in symptomatic tumor-related hypercalcemia: A prospective randomized crossover trial
|
Thürlimann, B.
|
|
1992
|
3 |
8 |
p. 619-623
|
article
|
| 23 |
Original article: Response after withdrawal of tamoxifen and progestogens in advanced breast cancer
|
Howell, A.
|
|
1992
|
3 |
8 |
p. 611-617
|
article
|
| 24 |
Original article: Subsets of tumors responsive to cisplatin or carboplatin combinations in patients with carcinoma of unknown primary site
|
Pavlidis, N.
|
|
1992
|
3 |
8 |
p. 631-634
|
article
|
| 25 |
Original article: The role of age at menarche and at menopause on breast cancer risk: Combined evidence from four case-control studies
|
La Vecchia, C.
|
|
1992
|
3 |
8 |
p. 625-629
|
article
|
| 26 |
Original article: Treatment with alpha-interferon versus alpha-interferon in combination with streptozocin and doxorubicin in patients with malignant carcinoid tumors: A randomized trial
|
Janson, F. Tiensuu
|
|
1992
|
3 |
8 |
p. 635-638
|
article
|
| 27 |
Perhaps not everyone knows that…
|
|
|
1992
|
3 |
8 |
p. 584-585
|
article
|
| 28 |
Radon levels too high in Swiss and British studies
|
|
|
1992
|
3 |
8 |
p. 582-582
|
article
|
| 29 |
Review: Allergic reactions to cytotoxic drugs - an update
|
O'Brien, M. E. R.
|
|
1992
|
3 |
8 |
p. 605-610
|
article
|
| 30 |
Rio: Just an occasion to go swimming?
|
|
|
1992
|
3 |
8 |
p. 582-582
|
article
|
| 31 |
Short report: Bi-weekly 2-day schedule of high-dose folinic acid, 5-fluorouracil bolus and infusion in pretreated advanced epithelial ovarian cancer: A phase II study
|
Louvet, C.
|
|
1992
|
3 |
8 |
p. 657-658
|
article
|
| 32 |
Short report: Multicenter phase II trial of brequinar sodium in patients with advanced melanoma
|
Natale, R.
|
|
1992
|
3 |
8 |
p. 659-660
|
article
|
| 33 |
Short report: Treatment of resistant tumor-induced hypercalcemia with escalating doses of pamidronate (APD)
|
Pecherstorfer, M.
|
|
1992
|
3 |
8 |
p. 661-663
|
article
|
| 34 |
Special article: The epidemiology of acquired immunodeficiency syndrome and associated tumours in Europe
|
Serraino, D.
|
|
1992
|
3 |
8 |
p. 595-603
|
article
|
| 35 |
Supportive Care in Cancer
|
|
|
1992
|
3 |
8 |
p. 668-668
|
article
|
| 36 |
The above letter was referred to the author, who responds as follows:
|
Dodwell, D. J.
|
|
1992
|
3 |
8 |
p. 665-665
|
article
|
| 37 |
The American Congress questions meta-analysis
|
|
|
1992
|
3 |
8 |
p. 582-582
|
article
|
| 38 |
The University of Berne, Switzerland (Faculty of Medicine/Inselspital)
|
|
|
1992
|
3 |
8 |
p. 663-663
|
article
|
| 39 |
To fight AIDS, the Swiss Government ready to provide heroin
|
|
|
1992
|
3 |
8 |
p. 583-583
|
article
|
Journal description